CDXC ChromaDex
- 3.660
- +0.120+3.39%
- 3.680
- +0.020+0.55%
ChromaDex News
ChromaDex Analyst Ratings
ChromaDex Analyst Ratings
Chromadex's Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating: An Analysis of Jeffrey Cohen's Recommendations
Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE), Chromadex (CDXC) and Glaukos (GKOS)
HC Wainwright & Co. Reiterates Buy on ChromaDex, Maintains $5 Price Target
ChromaDex Analyst Ratings
H.C. Wainwright Sticks to Its Buy Rating for Chromadex (CDXC)
H.C. Wainwright Keeps Their Buy Rating on Chromadex (CDXC)
HC Wainwright & Co. Reiterates Buy on ChromaDex, Maintains $5 Price Target
HC Wainwright Adjusts Price Target on ChromaDex to $5 From $5.50, Keeps Buy Rating
HC Wainwright & Co. Maintains Buy on ChromaDex, Lowers Price Target to $5
B. Riley Trims ChromaDex's Price Target to $2 From $2.10 After Mixed Q4 Metrics, Keeps Neutral Rating
ChromaDex Analyst Ratings
H.C. Wainwright Reaffirms Their Buy Rating on Chromadex (CDXC)
ChromaDex Is Maintained at Buy by HC Wainwright & Co.
ChromaDex Price Target Cut to $5.50/Share From $7.00 by HC Wainwright & Co.
HC Wainwright Adjusts Price Target on ChromaDex to $5.50 From $7, Reiterates Buy Rating
ChromaDex Analyst Ratings
HC Wainwright & Co. Maintains Buy on ChromaDex, Lowers Price Target to $5.5
ChromaDex Downgraded at Oppenheimer Citing Further Pressure on Topline
Analysis
Price Target
No Data
